Skip to content
The Nexus
DossierENTITY

Hikma Pharmaceuticals USA

Coverage of Hikma Pharmaceuticals USA in the Nexus archive.

Earliest in view: Jun 5 · 20:00 UTCMost recent: Jun 5 · 20:00 UTC
Co-mentioned in this coverage
Amarin Pharmaorganization1Justice Ketanji Brown Jacksonperson1Vascepatopic1U.S. Court of Appeals for the Federal Circuitorganization1CV indicationtopic1SH indicationtopic1
Recent coverage
  • BUSINESSJun 5 · 20:00 UTCSCOTUSBLOG
    Justices reject holding generic pharmaceutical manufacturers liable for decisions of pharmacists about prescribing their products

    The Supreme Court unanimously ruled that generic drug manufacturer Hikma Pharmaceuticals cannot be held liable for patent infringements by branded drugmaker Amarin Pharma, rejecting claims that Hikma's labeling, press releases, and website statements actively induced infringement. The case centered on whether Hikma's generic version of Vascepa, used interchangeably with Amarin's patented drug for cardiovascular and hypertriglyceridemia treatments, could be blamed for doctors and pharmacists using the generic for patented purposes.

Hikma Pharmaceuticals USA · Dossier · The Nexus